Title

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a velid OMB control number

		STATEMENT UNDER 37 CFR 3.73(b)
Ap	plicant	atent Owner: Alan DRIZEN, et al.
Ap	plicatio	No./Patent No. 90/011,847 / 5,897,880 Filed/issue Date: August 4, 2011 / April 27, 1999
	ed:	OPICAL DRUG PREPARATIONS
Gly	coBio	ciences, inc.
(Na	me of As	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
sta	tes tha	is:
1.	X	the assignee of the entire right, title, and interest in;
2.		an assignee of less than the entire right, title, and interest in The extent (by percentage) of its ownership interest is
3.		the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the	patent	pplication/patent identified above, by virtue of either:
A.		An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.
OR		opy distribute is adjactive.
В.	\times	A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
		From: Alan Drizen (Estate of Alan Drizen), et al. To: L.A.M. Pharmaceutical, Corp.
		The document was recorded in the United States Patent and Trademark Office at Reel 027687 , Frame 0752 , or for which a copy thereof is attached.
		2 From: L.A.M. Pharmaceutical, Corp. To: GlycoBioSciences, Inc.
		The document was recorded in the United States Patent and Trademark Office at Real 021661 Frame 0330 or for which a copy thereof is attached.
		3. From:
		The document was recorded in the United States Patent and Trademark Office at
		Real, Frame or for which a copy thereof is attached.
		Additional documents in the chain of title are listed on a supplemental sheet(s).
	As or o	quired by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, nourently is being, submitted for recordation pursuant to 37 CFR 3.11.
	acc acc	E: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in dagges with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The	under	gned (M) se title is supplied below) is authorized to act on behalf of the assignee.
,	S	NACH 22,2012 Date
Kev	in Dri	n President

This collection of information is required by 37 CFR 3.75(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Corridentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including processly in epiperson. Lormonisative fig. governor or 3 of U.S. L. X. data of Left 1.11 and 1.14. The conservor is estimated to base 1 amounts to Complete, incurrange underling, preparing via an identified specification from the full SPTO. There will very depending upon the foreigned update case. Any comments not his ascorated the part or gain as to complete the first own must be underly depended to complete the complete depended for reducing this butter, should be sent to the Child altornation Officer, U.S. Palent and Trademark Officer, Department of Comments 2 Co. St. Aff. Association (J. A. 20 and 3.14400. ON OTH SERIOR DEPENDED COMPLETED FORMER TO THIS ADDRESS TO THIS ADDR for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

Printed or Typed Name

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(0)(2); (2) furnishing of the information solicitied is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office have not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or existance or the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodifications.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the second.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine sues, to the International Bureau of the Model Intellegency Cooperation Programment on the Patent Cooperation Treatment of the Model Intellegency Cooperation Programment on the Patent Cooperation Treatment of the Patent Cooperation Programment on the Patent Cooperation Programment on the Patent Cooperation Treatment on the Patent Cooperation Programment Cooperation Pro
- World Intellectual Property Organization, pursuant to the Patient Cooperation Treety, 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (24 U.S. C. 2186).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 157. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued natent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or requisition.